Pinnacle West Stock To Go Ex-dividend Tomorrow (PNW)

NEW YORK ( TheStreet) -- The ex-dividend date for Pinnacle West Capital Corporation (NYSE: PNW) is tomorrow, January 30, 2014. Owners of shares as of market close today will be eligible for a dividend of 57 cents per share. At a price of $51.90 as of 9:50 a.m. ET, the dividend yield is 4.4%.

The average volume for Pinnacle West has been 955,400 shares per day over the past 30 days. Pinnacle West has a market cap of $5.71 billion and is part of the utilities sector and utilities industry. Shares are down 1.8% year to date as of the close of trading on Tuesday.

Pinnacle West Capital Corporation, through its subsidiary, Arizona Public Service Company, provides retail and wholesale electric services primarily in the State of Arizona. The company has a P/E ratio of 14.1, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Pinnacle West as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and attractive valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Pinnacle West Ratings Report.

See our dividend calendar or top-yielding stocks list.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing